NEW YORK (dpa-AFX Broker) – The US analysis company Bernstein Research left the rating for Bayer at “Outperform” with a price target of 89 euros. The phrase “This time it’s different” could actually apply under the new CEO Bill Anderson, analyst Gunther Zechmann wrote in a study available on Monday. Activist shareholders put pressure on them, the latest results had been disappointing, so Zechmann said Anderson could seriously consider shooting down the “silver bullet Consumer Health”. He sees some strategic options for the self-medication business. The optimal case is a merger with the competitor Haleon. “But two are needed for a tango dance,” says Zechmann./ag/tih
Publication of the original study: 08.07.2023 / 18:37 / UTC
First distribution of the original study: 07/10/2023 / 04:05 / UTC
———————–
dpa-AFX Broker – the trader news from dpa-AFX
———————–
Selected leverage products on Bayer
With knock-outs, speculative investors can participate disproportionately in price movements. Simply select the lever you want and we will show you suitable open-end products on Bayer
Leverage must be between 2 and 20